viewSkinBioTherapeutics PLC

SkinBioTherapeutics reports progress in cosmetic programme and food supplement trial

The ‘self managed’ psoriasis food supplement trial is expected to accelerate the timing of readout and allow for a “significantly earlier commercial launch than originally planned”

SkinBioTherapeutics PLC - SkinBioTherapeutics reports progress in cosmetic programme and food supplement trial

SkinBioTherapeutics PLC (LON:SBTX) has updated investors on the progress of its cosmetic skincare programme and a psoriasis food supplement trial.

The AIM-listed firm said Sederma, its partner in the cosmetics programme and a division of Croda International PLC (LON:CRDA), has successfully replicated the lysate manufacturing process and achieved the same performance from the company’s SkinBiotix technology and is now working to validate a scale up of the manufacturing process at different volume levels.

WATCH: SkinBioTherapeutics assessing options for a 'rapid trial' of its food supplement

SkinBio said the project is progressing in line with the original plan and has not been impacted by the coronavirus pandemic, adding that any results from the programme will be sold to Croda's global portfolio of Personal Care customers, with the company receiving tiered royalties based on global sales revenues on any products developed in the partnership.

Meanwhile, the firm said in light of current restrictions on non-coronavirus related human studies, it has established a protocol for its ‘ self-managed’ psoriasis food supplement trial and was proceeding with the study.

Participants suffering from mild to moderate psoriasis will be invited to participate in a human study in which they will be provided with samples of AxisBiotix Ps to self-administer over eight weeks and track the impact of the food supplement on their skin condition. They will then submit their findings periodically through a bespoke mobile app, avoiding the need for clinical attendance.

SkinBio said this will accelerate the timing of readout compared to the previously envisaged conventional study, and if the findings were positive this will allow for a “significantly earlier commercial launch than originally planned”. The trial is expected to begin in early 2021.

"We have seen significant positive progress made on the first of our commercial programmes in recent weeks. In such an important scientific milestone, it is reassuring and provides validation of our approach that Sederma has been able to replicate the activity of the SkinBiotix technology and is pushing ahead with the next steps of the project”, SkinBio chief executive Stuart Ashman said in a statement.

"In addition, establishing a clear pathway to commencing a food supplement trial to manage symptoms associated with psoriasis is a great step forward for our collaboration with Winclove. The progress made in such a short period of time is testament to the combined efforts of the SkinBioTherapeutics and Winclove team", he added.

Quick facts: SkinBioTherapeutics PLC

Price: 16.777 GBX

Market: AIM
Market Cap: £26.15 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...



SkinBioTherapeutics raise £4m to expand SkinBiotix technology in oral and...

Skinbiotherapeutics Plc's (LON:SBTX) Doug Quinn talks to Proactive's Katie Pilbeam on their plans for the £4m raised from existing and new institutions to fund work on new product applications. Quinn explains how they plan to expand skin biotics technology into oral and healthcare as...

on 14/10/20

3 min read